Earnings are in.
Immunity Bio prints a revenue number at the higher end of all 3 analysts estimates. 50.7 vs consensus 49.2
Analysts are professionals at getting things "nearly accurate". This 3.25% beat is fine, but its not going to move the stock up or (significantly) down.
The more countries that come online + the more labels are expanded in America, the more upside the stock will have.
Lets temper expectations for now, and listen closely to the Earnings call by Richard Adcock on Friday.
Earnings are in.....i will go live soon to discuss. Moving up the timeline from 9am eastern to 8:30ish
$IBRX